Science | 11 September 2024 | News
IISc explores ways to control tumour progression
In a new study published in the Journal of Cell Science, researchers at the Indian Institute of Science (...Read more
Opinion | 01 September 2024 | Interviews
What are the primary challenges before the API sector in India, particularly concerning supply chain disruptio...Read more
MedTech | 10 September 2024 | News
Atal Innovation Mission, NITI Aayog hosts 20th MedTech Mitra technical advisory meeting
Atal Innovation Mission (AIM), NITI Aayog recently hosted the 20th Technical Advisory Committee (TAC...Read more
Start-ups | 13 September 2024 | News
Sleep apnea-focused startup Dormir Bien to initiate sleep wellness business in India
Recognising the vital role sleep plays in physical and mental well-being, Dormir Bien is set to revo...Read more
Supplier | 06 September 2024 | News
Qiagen to develop first QIAstat-Dx IVD panel for neurodegenerative applications
Qiagen has entered into a collaboration with Eli Lilly and Company to support the development of a QIAstat-Dx ...Read more
People | 11 September 2024 | News
MedGenome appoints Dr Amit Kakar as New Chairman of the Board
Bengaluru-based MedGenome, a leading global genomics-driven diagnostics and research services company, ha...Read more
Academics | 06 September 2024 | News
Bengaluru-based Aster Health Academy, a pioneering ed-tech institution dedicated to advancing professional edu...Read more
Text blogs | 04 September 2024 | Views
Strengthening ecosystem for medical tourism in India
India's prominence in the global medical tourism industry is underpinned by a blend of cost-effective treatmen...Read more
Can India Reclaim API Throne from China?
Despite having the third-largest pharmaceutical industry by volume in the world and being the largest manufacturer of generic medicines globally, India is heavily dependent on China for imports of raw materials, Key Starting Materials (KSMs), and Active Pharmaceutical Ingredients (APIs). India is the source of around 60,000 generic brands across 60 therapeutic categories and manufactures more than 500 different APIs. However, India imports about 70 per cent of its APIs from China as it’s a cheaper option than manufacturing them domestically. There were 58 APIs in which India was heavily dependent on China. In the case of 45 APIs, India was dependent on China for 100 per cent of imports. Out of these 58 APIs, 29 APIs are manufactured through fermentation and 29 APIs are manufactured through chemical synthesis. The Department of Pharmaceuticals has drawn up a list of 56 APIs to prioritise them for the Make-in-India initiative. These include APIs or bulk drugs that go into the making of essential drugs, such as antibiotics, anti-HIV medicines, and the humble but indispensable paracetamol. The plan to make APIs in India has been in the works for some time but the Council of Scientific and Industrial Research (CSIR ) was engaged only recently. Let’s see how these steps taken by the government help to promote the production of KSMs and APIs in India in the coming years.
For Feedback, please email us at: communications@mmactiv.com